In summary, the present study suggests that SIRT4 immunohistochemistry may be a reliable prognostic biomarker in BLCA and that SIRT4 plays the role of tumor suppressor in BLCA. This evidence concerns the gene SIRT4 and bladder transitional cell carcinoma.